Why do South Asians have lower BMI thresholds for GLP-1 eligibility in India?

Under Endocrine Society of India (ESI 2025) and RSSDI guidelines, South Asians carry a 'thin-fat phenotype' characterized by higher abdominal/visceral fat and metabolic risk at lower body weights. Eligibility in India begins at BMI ≥ 27 (or BMI ≥ 25 with comorbidities like T2D or PCOS), compared to BMI ≥ 30 in Western populations.

What is the difference between Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro)?

Semaglutide is a single GLP-1 receptor agonist (averaging ~14.9% weight loss in STEP-1 trial). Tirzepatide is a dual GIP/GLP-1 receptor agonist (Mounjaro), averaging ~22.5% weight loss in SURMOUNT-1 trial.

Why is a slow titration schedule mandatory when starting GLP-1 medications?

Gradual titration allows the gastrointestinal system to comfortably adapt to GLP-1 receptor stimulation, minimizing common side effects like nausea, acid reflux, and digestion changes while finding the lowest effective maintenance dose.

prescriptions

Instant Prescription Path · India

Qualified for GLP-1 Therapy in India?

Speak to an InGoodHands Doctor today for blood panel evaluation and prescription fulfillment across all major Indian cities.

Assess Eligibility arrow_downward

verified_user Medically reviewed by Dr. Brij Teli | Medical Director, InGoodHands India · Updated July 2026

GLP-1 & Ozempic Eligibility Calculator (South Asian ESI 2025 Adjusted)

Calculate your personalized weight loss timeline and clinical eligibility for Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro) in India using ESI 2025 and FDA guidelines.

tune 1. Personalize Your Physical & Clinical Profile

Provide your measurements to calculate your BMI under South Asian or FDA criteria.

public Clinical Guideline Benchmark India ESI 2025 Standard

verified

South Asian / Indian Obesity Guidelines (ESI 2025 / RSSDI) Specially adjusted for the thin-fat phenotype (higher visceral adiposity at lower body weights). Clinical qualification begins at BMI ≥ 27 (or BMI ≥ 25 with metabolic comorbidities like PCOS, T2D, or Hypertension).

Height Input Mode

CM FT/IN

Current Weight

monitor_weight kg

Range: 35 - 300 kg

Target Weight

adjust kg

Must be less than current weight

Height

height cm

Used to calculate starting BMI

Age (Years)

cake yrs

Must be 18 or older to enroll

health_and_safety

Absolute Safety Screening (Hard Stops)

Strict clinical contraindications mandated by FDA & Indian Medical Council guidelines.

Required Check

Please select any of the following safety conditions that apply to you. Prescribing is strictly restricted if any hard stop criteria are present:

Thyroid Cancer / MTC History Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

Absolute Stop

Pancreatitis Documented history of Acute or Chronic Pancreatitis.

Absolute Stop

Pregnancy / Breastfeeding Currently pregnant, breastfeeding, or actively planning conception within the next 60 days.

Absolute Stop

Target Medication Program

Semaglutide

Ozempic/Wegovy: Average 14.9% loss over 68 weeks.

Tirzepatide

Mounjaro: Average 22.5% loss over 72 weeks.

Results Projection

Expected Loss (48 Wks) —

Timeline to Target

—

Recommended Daily Targets (Muscle Preservation)

Calories —

Protein —

Carbs —

Fats —

💡 High protein intake is essential to defend lean muscle mass during GLP-1 weight reduction.

Calculated Starting BMI: — Loading...

Target Weight Feasibility

Weight Projection Timeline Weeks 0 to 48

chat

Get Full Report on WhatsApp Send your clinical eligibility score & titration roadmap directly to WhatsApp.

assignment Your Personalized Weight Loss Plan

Based on your goals, you'll need approximately — weeks to lose — kg and reach your target weight of — kg using —.

📋 Your Success Checklist

✅

Moderate Calorie Deficit Reduce daily intake by 500-750 calories

✅

Daily Protein Target Consume —g of protein daily

✅

Resistance Training Complete 2-3 strength workouts per week

✅

Daily Hydration Drink — liters of water daily

medical_services 2. Medical Consultation & Lead Intake

Submit your details for doctor review or to schedule your medical consultation in India.

Full Name

person

WhatsApp Phone Number

+91

phone

biotech Add GLP-1 Baseline Diagnostic Blood Panel Includes home sample collection for HbA1c, Fasting Blood Sugar, Lipid Profile, Liver (LFT), and Kidney (KFT) function tests prior to doctor consult.

InGoodHands Clinical Protocol Summary

medical_information Endocrinologist Video Consultation: Comprehensive review of clinical history and metabolic baseline (₹349 consult fee).

lab_research Diagnostic Blood Panel: Analysis of thyroid (TSH), blood sugar (HbA1c), liver, and kidney health markers to confirm candidacy.

monitoring Precision Dose Titration: Gradual titration schedules monitored weekly to manage side effects and adapt to lowest effective doses.

Update your inputs to verify clinical eligibility criteria.

🔒 Your health history is fully private and evaluated strictly under medical supervision guidelines.

shield_with_heart

Medical & Clinical Disclaimer (India)

This eligibility assessment is a statistical screening tool based on Endocrine Society of India (ESI 2025) and FDA criteria for informational purposes only. It does not constitute medical advice, diagnosis, or a prescription.

GLP-1 receptor agonists (Semaglutide, Tirzepatide) are prescription-only medications in India. Treatment authorization requires direct physician consultation, comprehensive baseline blood work (HbA1c, LFT, KFT, Thyroid), and continuous clinical supervision by an endocrinologist.

The Clinical Evidence & Guidelines Behind Our Calculator

To maintain strict medical accuracy for Indian patients under YMYL health standards, our computational models incorporate peer-reviewed clinical trial data alongside ethnicity-adjusted guidance from the Endocrine Society of India (ESI 2025).

ESI 2025 Guidelines (South Asian Criteria)

Due to higher visceral fat at lower body weights, the Endocrine Society of India (ESI 2025) and RSSDI set lower BMI eligibility cut-offs (BMI ≥ 27 for obesity, BMI ≥ 25 with comorbidities) compared to Western criteria.

The STEP-1 Trial — Semaglutide Efficacy

Published in NEJM, the STEP-1 trial evaluated once-weekly Semaglutide over 68 weeks, achieving an average total body weight loss of 14.9% Wilding et al., 2021, PMID: 33567185 open_in_new.

The SURMOUNT-1 Trial — Tirzepatide Efficacy

Evaluating dual GIP/GLP-1 receptor agonist Tirzepatide (Mounjaro), participants escalating to 15 mg weekly achieved an average weight reduction of 22.5% over 72 weeks Jastreboff et al., 2022, PMID: 35658024 open_in_new.

GLP-1 Clinical Benchmarks in India

Medication Pathway	Form Factor in India	Average Weight Loss %	Standard Titration Schedule
Semaglutide (Ozempic/Wegovy)	Once-Weekly Subcutaneous Injectable	~14.9% of body weight	0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg
Tirzepatide (Mounjaro)	Once-Weekly Subcutaneous Injectable	~22.5% of body weight	2.5mg → 5.0mg → 7.5mg → 10mg → 12.5mg → 15mg

FAQ & Clinical Guidance

Frequently Asked Questions About GLP-1 & Ozempic in India

Under Endocrine Society of India (ESI 2025) and RSSDI guidelines, South Asians exhibit a "thin-fat phenotype"—possessing higher abdominal visceral fat, higher liver fat, and insulin resistance at lower body weights. Eligibility in India begins at BMI ≥ 27 (or BMI ≥ 25 with comorbidities like Prediabetes, T2D, or PCOS), whereas Western guidelines start at BMI ≥ 30.

Semaglutide (Ozempic, Wegovy) acts purely on GLP-1 receptors to slow gastric emptying and suppress appetite. Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist, targeting two metabolic pathways simultaneously. In clinical trials, Tirzepatide demonstrated higher average weight reduction (~22.5%) compared to Semaglutide (~14.9%).

Escalating doses too quickly can cause gastrointestinal discomfort such as nausea, reflux, or changes in bowel habits. Starting at lower doses (e.g. 0.25mg Semaglutide or 2.5mg Tirzepatide) allows your digestive system to adapt comfortably while maintaining sustained appetite suppression.